.jpeg)
2026-02-06 06:18:41
Biktarvy (Bictegravir, Emtricitabine, Tenofovir Disoproxil Fumarate) is a single-tablet, triple-antiretroviral compound containing Bictegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate, which rapidly blocks viral replication through dual inhibition of integrase and reverse transcriptase. The success rate of reducing viral load to the detection limit within 48 hours is over 80%, and the rate of virological failure after 96 weeks of long-term treatment is less than 1%. It has good safety (mainly mild to moderate adverse reactions), significantly improves CD4+ cell count, and is a preferred first-line treatment for HIV-1 infection. It should be used under the guidance of a doctor and in accordance with prescribed standards.
2026-02-06 03:00:54
Denosumab is an important biologic agent widely used in the treatment of osteoporosis, giant cell tumors of bone, and bone-related events caused by bone metastasis of solid tumors. By inhibiting the activity and survival of osteoclasts, it effectively increases bone density and reduces the risk of fractures, playing a key role in the treatment of skeletal diseases. Although denosumab has a good overall safety profile, like all drugs, it may also bring some potentially serious side effects, especially in specific situations such as long-term use or individual sensitivity. Therefore, both patients and doctors need to have a full understanding of this so as to identify and manage it in a timely manner.
